Abstract
Gaucher disease is the most frequent lysosomal storage disorder. It is an autosomal recessive condition caused by a functional deficiency of the enzyme β-glucosidase, which results in accumulation of glucosylceramide in lysosomes of macrophages of the reticuloendothelial system. The most prevalent form of Gaucher disease is type 1 variant, a form that does not affect the central nervous system. Progressive accumulation of Gaucher cells leads to multiple manifestations, including hepatosplenomegaly, anemia, thrombocytopenia, growth retardation, pulmonary infiltrates, and skeletal disease. Radiographically demonstrable involvement results from five basic processes: marrow replacement, generalized osteopenia, skeletal resorption due to heavily involved marrow leading to focal lytic lesions (sometimes with extraosseous extensions, also known as gaucheromas), acute focal bone disease (such as osteonecrosis, especially collapse of the femoral head, osteomyelitis, and fractures), and the Erlenmeyer flask deformity, a highly characteristic but inconstant and not pathognomonic, modeling abnormality of the distal femur. Dual-energy X-ray absorptiometry demonstrates low levels of bone density and is superior to quantitative CT scans in Gaucher disease patients, because it takes into account cortical bone loss. Magnetic resonance imaging is the cornerstone of skeletal imaging in Gaucher disease. Affected bone marrow characteristically demonstrates low signal intensity on both T1-weighted and nonfat-suppressed T2-weighted imaging sequences, and it is relatively hyperintense on fat-suppressed sequences, such as short tau inversion recovery. The pattern of involvement can be homogeneous or heterogeneous. Gaucher disease extends into the marrow in a fairly predictable pattern, which reverses the sequence of normal marrow conversion during childhood, the process known as reconversion, as may also be seen in other marrow-replacing disorders. The most sensitive MRI technique that is currently available to quantify the extent of marrow replacement is quantitative chemical shift imaging. This technique quantifies the fat content in bone marrow by using the difference in resonant frequencies between fat and water. The fat fraction is decreased severalfold in patients with Gaucher disease, compared with normal individuals, as Gaucher cells displace the normal triglyceride-rich adipocytes in bone marrow. A number of semiquantitative scoring systems have been created that use more widely available MRI technology. These include the Düsseldorf Gaucher score, the vertebra-to-disk ratio, and the bone marrow burden score, as well as other scales based on the known pattern of disease progression and visual determination of the presence of disease. Radioisotope scans, including technetium (Tc)-99 m sulfur colloid, 99mTc sestamibi, and bone scanning after inhalation of xenon gas, have also been used to evaluate the marrow changes of Gaucher disease. Ultrasonography may be used to assess volume changes in the liver and spleen. Intravenous enzyme replacement therapy (ERT) is an effective treatment for the systemic manifestations of Gaucher disease. ERT has the potential to prevent serious skeletal complications as well as suppress disease manifestations. More recently developed oral substrate reduction therapies attenuate the rate of synthesis of glucocerebroside and provide an alternative for symptomatic adult patients for whom ERT is not an option. Imaging helps guide management decisions by assessing the sites and degrees of organ involvement, monitoring treatment response, and detecting complications.
Similar content being viewed by others
References
Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosides: II. Evidence of an enzymatic deficiency: Gaucher disease. Biochem Biophys Res Commun. 1965;18:221–5.
Meikle PJ, Hopwood JJ, Clague AE, et al. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249–54.
Mankin HJ, Rosenthal DI, Xavier R. Gaucher disease. Curr Concepts Rev. 2001;83A:748–62.
Thanopoulos BD, Frimas CA, Mantagos SP, et al. Gaucher disease: treatment of hypersplenism with splenic embolization. Acta Paediatr Scand. 1987;76:1003–7.
Hill SC, Damaska BM, Tsokos M, et al. Radiographic findings in type 3b Gaucher disease. Pediatr Radiol. 1996;26:852–60.
Stowens DW, Teitelbaum SL, Kahn AJ, et al. Skeletal complications of Gaucher disease. Medicine (Baltimore). 1985;64:310–22.
DeFriend DE, Brown AEM, Hutton CW, et al. Mannosidosis: an unusual cause of a deforming arthropathy. Skelet Radiol. 2000;29:358–61.
Faden MA, Krakow D, Ezgu F, et al. The Erlenmeyer flask bone deformity in the skeletal dysplasias. Am J Med Genet A. 2009;149A:1334–45.
Li JK, Birch PD, Davies AM. Proximal humeral defects in Gaucher disease. Br J Radiol. 1988;61:579–83.
Kaloterakis A, Cholongitas E, Pantelis E, et al. Type I Gaucher disease with severe skeletal destruction, extraosseous extension, and monoclonal gammopathy. Am J Hematol. 2004;77:377–80.
Hermann G, Shapiro R, Abdelwahab IF, et al. Extraosseous extension of Gaucher cell deposits mimicking malignancy. Skelet Radiol. 1994;23:253–6.
Poll LW, Koch JA, vom Dahl S, et al. Type I Gaucher disease: extraosseous extension of skeletal disease. Skelet Radiol. 2000;29:15–21.
Fiore CE, Barone R, Pennisi P, et al. Bone ultrasonometry, bone density, and turnover markers in type 1 Gaucher disease. J Bone Miner Metab. 2002;20:34–8.
Charrow J, Andersson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr. 2004;144:112–20.
Rosenthal DI, Scott JA, Barranger J, et al. Evaluation of Gaucher disease using magnetic resonance imaging. J Bone Joint Surg Am. 1986;68:802–8.
Baur A, Stabler A, Lamerz R, et al. Light chain deposition disease in multiple myeloma: MR imaging features correlated with histopathological findings. Skelet Radiol. 1998;27:173–6.
Johnson L, Hoppel B, Gerard E, et al. Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease. Radiology. 1992;182:451–5.
Maas M, Hollak CEM, Akkerman EM, et al. Quantification of skeletal involvement in adults with type I Gaucher disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AJR Am J Roentgenol. 2002;179:961–5.
Rosenthal DI, Barton NW, McKusick KA, et al. Quantitative imaging of Gaucher disease. Radiology. 1992;185:841–5.
Rosenthal DI, Doppelt SH, Mankin HJ, et al. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics. 1995;96:629–37.
Hollak C, Maas M, Akkerman E, et al. Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis. 2001;27:1005–12.
Poll LW, Willers R, Häussinger D, et al. MRI bone marrow findings in 63 patients with type I Gaucher disease. Rofo. 2010;182:1–7.
Vlieger EJP, Maas M, Akkerman EM, et al. The application of the vertebra-disc ratio in a population of patients with Gaucher disease. Proc Intl Soc Magn Reson Med 2000;2131 [abstract].
Maas M, van Kuijk C, Stoker J, et al. Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging—initial experience. Radiology. 2003;229:554–61.
Hermann G, Shapiro RS, Abdelwahab IF, et al. MR imaging in adults with Gaucher disease type I: evaluation of marrow involvement and disease activity. Skelet Radiol. 1993;22:247–51.
Vlieger EJ, Maas M, Akkerman EM, et al. Vertebra disc ratio as a parameter for bone marrow involvement and its application in Gaucher disease. J Comput Assist Tomogr. 2002;26:843–8.
Poll LW, Cox ML, Godehardt E, et al. Whole body MRI in type I Gaucher patients: evaluation of skeletal involvement. Blood Cells Mol Dis. 2011;46:53–9.
Terk MR, Esplin J, Lee K, et al. MR imaging of patients with type I Gaucher disease: relationship between bone and visceral changes. AJR Am J Roentgenol. 1995;165:599–604.
Mariani G, Filocamo M, Giona F, et al. Severity of bone marrow involvement in patients with Gaucher disease evaluated by scintigraphy with 99mTc-sestamibi. J Nucl Med. 2003;44:1253–62.
Barton NW, Brady RO, Dambrosia JM, et al. Dose-dependent responses to macrophage-targeted glucocerebrosidase in a child with Gaucher disease. J Pediatr. 1992;120:277–80.
Whittington R, Goa KL. Alglucerase: a review of its therapeutic use in Gaucher disease. Drugs. 1992;44:72–93.
Bembi B, Ciana G, Mengel E, et al. Bone complications in children with Gaucher disease. Br J Radiol. 2002;75(Suppl. 1):A37–44.
Poll LW, Koch JA, vom Dahl S, et al. Magnetic resonance imaging of bone marrow changers in Gaucher disease during enzyme replacement therapy: first German long-term results. Skelet Radiol. 2001;30:496–503.
Terk MR, Dardashti S, Liebman HA. Bone marrow response in treated patients with Gaucher disease: evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen volume. Skelet Radiol. 2000;29(10):563–71.
Schiffmann R, Mankin H, Dambrosia JM, et al. Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis. 2002;28:288–96.
Figueroa ML, Rosenbloom BE, Kay AC, et al. A less costly regimen of alglucerase to treat Gaucher disease. N Engl J Med. 1992;327:1632–6.
Pastores GM, Patel MJ, Firooznia H. Bone and joint complications related to Gaucher disease. Curr Rheumatol Rep. 2000;2:175–80.
Pastores GM, Barnett NL, Kolodny EH. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther. 2005;27:1215–27.
Elstein D, Hollak C, Aerts JM, et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis. 2004;27:757–66.
Pastores GM, Elstein D, Zimran A. Effect of miglustat on bone disease in adult type 1 Gaucher disease. Clin Ther. 2007;29:1645–54.
Elstein D, Dweck A, Attias D, et al. Oral maintenance clinical trial with miglustat for type 1 Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood. 2007;110:2296–301.
Giraldo P, Alfonso P, Atutxa K, et al. Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project. Haematologica. 2009;94:1771–5.
Pastores GM, Giraldo P, Cherin P, et al. Goal-oriented therapy with miglustat in Gaucher disease. Curr Med Res Opin. 2009;25:23–37.
Ficicioglu C. Review of miglustat for clinical management in Gaucher disease type 1. Ther Clin Risk Manage. 2008;4:425–31.
Itzchaki M, Lebel E, Dweck A, et al. Orthopedic considerations in Gaucher disease since the advent of enzyme replacement therapy. Acta Orthop Scand. 2004;75:641–53.
Iwase T, Hasegawa Y, Iwata H. Transtrochanteric anterior rotational osteotomy for Gaucher disease: a case report. Clin Orthop Relat Res. 1995;317:122–5.
Ringden O, Groth CG, Erikson A, et al. Ten years’ experience of bone marrow transplantation for Gaucher disease. Transplantation. 1995;59:864–70.
Suggested Readings
Degnan AJ, Ho-Fung VM, Ahrens-Nicklas RC, et al. Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement. Insights Imaging. 2019;10(1):70.
Katz R, Booth T, Hargunani R, et al. Radiological aspects of Gaucher disease. Skelet Radiol. 2011;40:1505–13.
Mankin HJ, Rosenthal DI, Xavier R. Gaucher disease. Curr Concepts Rev. 2001;83A:748–62.
Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol. 2004;41(4 Suppl. 5):4–14.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2023 Springer Nature Switzerland AG
About this entry
Cite this entry
Rosenthal, D.I., Gorbachova, T. (2023). Gaucher Disease. In: Pope, T., Bloem, J.L., Morrison, W.B., Wilson, D.J., White, L. (eds) Musculoskeletal Imaging. Springer, Cham. https://doi.org/10.1007/978-3-030-57376-8_75-1
Download citation
DOI: https://doi.org/10.1007/978-3-030-57376-8_75-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-57376-8
Online ISBN: 978-3-030-57376-8
eBook Packages: Springer Reference MedicineReference Module Medicine